Skip to main content
Premium Trial:

Request an Annual Quote

Richard Wagner, Owen Dempsey, Arthur Beaudet, Ellen Beasley, Keith Joho, Jeff Otto, Tom Ranken, John Fazio

Premium
Richard Wagner has joined SRU Biosystems as president and CEO, the company said last week. Wagner has also been named a member of the board of directors.
 
Wagner replaces Owen Dempsey, who resigned from the company to pursue other interests. Wagner had previously been an advisor to SRU Biosystems since 2002. Before that he served as executive vice president of research at Praecis Pharmaceuticals. He also has held positions at Phylos and Gilead Sciences.
 
Wagner holds a BSc in biochemistry from Trinity College and a PhD in chemistry from Brown University.
 

 
Arthur Beaudet, chair and professor of molecular and human genetics at Baylor College of Medicine, has won the American Society of Human Genetics’ Allan Award.
 
Beaudet's work is focused on epigenetics in human disease and genomic imprinting and diseases associated with mental retardation and autism.
 

 
Perlegen last week said it has tapped three new executives to join its staff:  Ellen Beasley, Keith Joho, and Jeff Otto.
 
Beasley will join the company as vice president of project management. She comes to the company from Celera, where she held the posts of senior director of therapeutics alliances, senior director of bioinformatics, and director of gene discovery.
 
Joho steps in as chief information officer after serving as senior VP of research and product management at Ingenuity Systems, and as VP of informatics and bioanalytical operations at SurroMed. Joho also was director of bioinformatics at Abgenix also served at Roche and at the Louisiana State University Medical Center in New Orleans.
 
Otto will take over the role of VP of production operations after having been an executive at Genaissance Pharmaceuticals and at Sequenom.
 

 
Tom Ranken plans to give up his role as CEO of VizX Labs and move into a post on the company’s board of directors, while John Thompson will take over the top spot, Ranken said in a letter last week.
 
Ranken said Thompson has “extensive experience in leadership roles” in a variety of businesses, including working in “venture capital, asset recovery, retail, information technology, financial services, distribution and production.”
 

 
Sequenom has appointed John Fazio to its board of directors. Fazio formerly was senior general practice partner at PricewaterhouseCoopers, where he had a 35-year career.

The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.